Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Drive communication plan and debate - Sharon McHale & Riia Järvenpää

92 views

Published on

On behalf of the WP5 Sharon McHale & Riia Järvenpää
DRIVE Annual Forum
17th -18th September 2018, Rome

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Drive communication plan and debate - Sharon McHale & Riia Järvenpää

  1. 1. Dissemination of Pilot Year Outcomes Communications Workshop Work Package 5 DRIVE Annual Forum 18 September 2018
  2. 2. • WP5 introductions • DRIVE communication channels • High-level dissemination plan • Q&A • Group Activity • Group Presentations • Wrap-Up Agenda
  3. 3. DRIVE Website at www.drive-eu.org • Features all public deliverables • Information on Data source, Methodology, Governance model, Analytical model and Infrastructure of the project
  4. 4. DRIVE on LinkedIn: https://www.linkedin.com/company /drive-project/
  5. 5. DRIVE at Twitter: @drive_eu #DRIVEflu
  6. 6. Web-based survey of PHIs & PHAs N=7 to date Current IVE communications adequate: >50% yes Additional IVE info required: age/risk, type, brand Recommended communication channels: conferences, publications, direct, news releases, websites, social media Frequency: regular/monthly about DRIVE activities Intention to share DRIVE results with stakeholders: yes Concerns: 1 about PPP, 1 about reconciliation of DRIVE findings with findings of other IVE studies Communications Survey
  7. 7. DRIVE Stakeholders DRIVE IMI European Science, Medicine & Health Societies Society at large ECDC WHO EMA CHMP Vaccine Manufacturers Public Health Institutes National Health Agencies European Commission European Patient & Consumer Health Groups European Medical & Nursing Schools HCPs Layer 3 Layer 1 European Influenza experts Research Partners & Collaborators Media Layer 2
  8. 8. Dissemination Objectives Primary Objective Ensure pilot year outcomes are communicated in a meaningful way to all stakeholder groups Secondary Objectives 1. Fulfil DRIVE’s commitment to transparency 2. Strengthen the profile and credibilty of DRIVE as public- private partnership dedicated to brand-specific IVE 3. Recruit additional research partners to DRIVE 4. Stimulate scientific discussion about innovative approaches to IVE research and potential synergies
  9. 9. Communications Challenges 1. Diverse technical understanding of stakeholders 2. Potential for misinterpretation of IVE estimates 3. Perception of public-private partnerships 3. Uncoordinated disemmination of outcomes
  10. 10. Key Messages 1. DRIVE is an IMI-funded public private partnership established in 2017 to build a sustainable platform for generating robust brand-specific influenza vaccine effectiveness data across Europe each year, as part of new EMA requirements. 2. DRIVE has established Project Governance, including an independent scientific review process, and an initial study platform, which was successfully tested through a pilot study in the 2017/18 season. 3. DRIVE calls for additional research partners to contribute data and expertise, enabling the Project to continue to improve the study platform and to work towards its longer term goal.
  11. 11. • Study Reports and Summaries • Results Slide Presentation & Poster • Infographics Key Communication Tools
  12. 12. DRIVE Infographic
  13. 13. High Level Plan Annual Forum Sept 17-18 Present Outcomes Seek feedback on Communications approach Execute Social Media Plan Study Reports Finalised October ESCAIDE Host webinars Direct email to Stakeholders Issues New Release Load reports onto DRIVE website Execute Social Media Plan Conferences & Publications 2019 Direct approach to potential partners
  14. 14. Annual pooled brand-specific IVE estimates Systematic review on bias & confounders Availability & use of brand information Laboratory methods Other methodological topics (sample size, pooling approaches etc.) The rationale of brand-specific IVE and PPP governance Scientific independence, intergrity & transparency Potential publications
  15. 15. Q&A
  16. 16. Acknowledgement DRIVE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777363, This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. Communications – Interactive session Acknowledgement DRIVE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777363, This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. Gael Dos Santos - GSK 18th September 2018, Rome
  17. 17. Instructions • Each group will brainstorm for 30’ to discuss what your stakeholder group would like to know from DRIVE about IVE. • Prepare a few bullet points for presentation highlighting the key points. • Each group will have a slot of 5’ divided as follows: • At the beginning of the work, each group need to assign: - One time keeper - One scribe/presenter - The facilitators for each group have been identified on the list.
  18. 18. Assigned groups 1. Regulatory Authorities – Pieter Neels 2. Public Health Institutes (PHI)/ National and supranational public health organisations Caterina Rizzo 3. Health Care Professionals - Topi Turunen 4. Researchers/Scientists Group 1 - Margarita Riera 5. Researchers/Scientists Group 2 - Marianne Van der Sande 6. Patients/Patient Organisations - Sam Nye 7. Media - Julien Guyomard
  19. 19. Questions to consider? - What would I like to know about the DRIVE IVE and when? - Are there any particular sensitivities/issues/risks about communicating to my stakeholder? - Does the Public Private Partnership matter? Why?
  20. 20. Questions/proposals

×